Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Cancer Biology Graduate Program, Washington University School of Medicine, St. Louis, MO 63110, USA.
Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Cancer Biology Graduate Program, Washington University School of Medicine, St. Louis, MO 63110, USA.
DNA Repair (Amst). 2024 Sep;141:103736. doi: 10.1016/j.dnarep.2024.103736. Epub 2024 Jul 31.
Homologous recombination (HR) is a high-fidelity DNA double-strand break (DSB) repair pathway. Both familial and somatic loss of function mutation(s) in various HR genes predispose to a variety of cancer types, underscoring the importance of error-free repair of DSBs in human physiology. While environmental sources of DSBs have been known, more recent studies have begun to uncover the role of endogenous base damage in leading to these breaks. Base damage repair intermediates often consist of single-strand breaks, which if left unrepaired, can lead to DSBs as the replication fork encounters these lesions. This review summarizes various sources of endogenous base damage and how these lesions are repaired. We highlight how conversion of base repair intermediates, particularly those with 5'or 3' blocked ends, to DSBs can be a predominant source of genomic instability in HR-deficient cancers. We also discuss how endogenous base damage and ensuing DSBs can be exploited to enhance the efficacy of Poly (ADP-ribose) polymerase inhibitors (PARPi), that are widely used in the clinics for the regimen of HR-deficient cancers.
同源重组(HR)是一种高保真的 DNA 双链断裂(DSB)修复途径。各种 HR 基因的家族性和体细胞功能丧失突变(s)易导致多种癌症类型,这突显了在人类生理学中准确修复 DSB 的重要性。虽然已经知道 DSB 的环境来源,但最近的研究开始揭示内源性碱基损伤在导致这些断裂中的作用。碱基损伤修复中间体通常由单链断裂组成,如果不修复,当复制叉遇到这些损伤时,就会导致 DSB。本文综述了内源性碱基损伤的各种来源以及这些损伤的修复方式。我们强调了碱基修复中间体,特别是那些 5'或 3'端受阻的中间体,如何转化为 DSB,成为 HR 缺陷型癌症中基因组不稳定性的主要来源。我们还讨论了内源性碱基损伤和随之而来的 DSB 如何被利用来增强聚(ADP-核糖)聚合酶抑制剂(PARPi)的疗效,PARPi 广泛用于 HR 缺陷型癌症的治疗方案。